Silicate clay loaded platinum nano-enzyme and application thereof

By coating platinum nanoenzymes on silicate clay, using its enrichment ability in the inflammatory site of the digestive tract, the absorption and toxicity of platinum-based nanoenzymes in the digestive tract are solved, and effective treatment of digestive tract inflammation is achieved and prevention.

CN119074764APending Publication Date: 2024-12-06CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411206130.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Platinum-based nanoenzymes are easily absorbed by digestive tract epithelial cells directly orally, and it is difficult to continuously exert enzyme-like activity and form divalent platinum ions in the cells, resulting in cytotoxicity.

Method used

Using silicate clay-loaded platinum nanoenzymes, the enrichment capacity of platinum nanoenzymes is enhanced by coating platinum nanoenzymes on silicate carriers, using organosilane-modified silicate clay to ensure that it is in the inflammatory site of the digestive tract. the continuous effect.

Benefits of technology

It effectively reduces the ROS level related to colorectal inflammation, significantly relieves digestive tract inflammation, enhances tissue repair ability, and demonstrates excellent ROS clearance effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074764A_ABST
    Figure CN119074764A_ABST
Patent Text Reader

Abstract

The invention discloses a silicate clay loaded platinum nano enzyme and application thereof. The silicate clay loaded platinum nano-enzyme comprises a silicate carrier and a platinum nano-enzyme, wherein the platinum nano-enzyme is loaded on the silicate carrier; the silicate carrier is organosilane modified silicate clay; the platinum nano enzyme is metal nanoparticles coated with platinum-based nano enzyme. According to the invention, through the loading effect of the silicate clay on the platinum-based nano-enzyme, the enrichment and accumulation of the platinum-based nano-enzyme on a digestive tract inflammation part after oral administration are enhanced, and through the continuous removal effect of the platinum-based nano-enzyme on ROS, the digestive tract inflammation disease is treated, relieved or prevented.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a platinum nanozyme loaded with silicate clay and an application thereof. Background Art

[0002] Nanozymes refer to all nanoparticles with activities similar to those of natural enzymes. Compared with natural enzymes, nanozymes have the advantage of being less susceptible to acid, alkali, and heat, and are more conducive to continuous and stable function in the body. Compared with the specificity of natural enzymes to substrates, nanozymes can exhibit multiple enzyme activities at the same time, and can also be superior to natural enzymes in terms of enzyme activity.

[0003] Nanozymes can be divided into metal nanozymes, metal oxide nanozymes and carbon-based nanozymes according to the materials. Among them, metal nanozymes have broad application prospects in disease diagnosis and treatment due to their low price, controllable morphology and good biocompatibility. Among metal nanozymes, platinum-based nanozymes have the characteristics of high reactivity and stable properties, and have gradually attracted widespread attention in the biomedical field. Under different preparation conditions, platinum-based nanozymes can exhibit activities such as peroxidase, catalase, and oxidase, and are currently used in many medical fields such as anti-inflammatory, antibacterial, and anti-tumor.

[0004] However, platinum-based nanozymes are easily absorbed by gastrointestinal epithelial cells when directly administered orally, making it difficult for them to continuously exert enzyme-like activity. At the same time, platinum-based nanozymes captured by cells are prone to form divalent platinum ions in lysosomes, producing cytotoxicity. Summary of the invention

[0005] In order to solve the technical problem that the existing platinum-based nanozymes are easily absorbed by the epithelial cells of the digestive tract when taken orally, the present invention provides a silicate clay-loaded platinum nanozyme and application thereof.

[0006] The technical solution adopted by the present invention is as follows:

[0007] A silicate clay-supported platinum nanozyme, comprising a silicate carrier and a platinum nanozyme, wherein the platinum nanozyme is supported on the silicate carrier;

[0008] The silicate carrier is organosilane-modified silicate clay;

[0009] The platinum nanozyme is a metal nanoparticle coated with a platinum-based nanozyme.

[0010] Further, the organosilane is selected from one or more of 3-aminopropyltriethoxysilane, N-(β-aminoethyl)-γ-aminopropyltrimethoxysilane, 3-aminopropyltrimethoxysilane, γ-diethylenetriaminepropylmethyldimethoxysilane, γ-aminopropyltriethoxysilane, N-(β-aminoethyl)-γ-aminopropyltrimethoxysilane, γ-aminopropyltriethoxysilane, N-(β-aminoethyl-γ-aminopropyl)methyldimethoxysilane, and γ-aminopropylmethyldiethoxysilane.

[0011] Furthermore, the silicate clay is selected from one or more of montmorillonite, attapulgite, diatomite, fluorite, diatomaceous earth, kaolin, illite, chlorite, sepiolite, zeolite and talc.

[0012] Furthermore, the metal nanoparticles are selected from one or more of gold nanoparticles, silver nanoparticles, chromium nanoparticles, copper nanoparticles, and lead nanoparticles.

[0013] In one embodiment of the present invention, the above-mentioned silicate clay-supported platinum nanozyme is prepared by the following steps:

[0014] Step 1, reducing a precursor of a platinum-based nanozyme with a reducing agent in an aqueous solution in which metal nanoparticles are dispersed, to obtain metal nanoparticles coated with the platinum-based nanozyme;

[0015] Wherein: the precursor of the platinum-based nanozyme can be chloroplatinic acid, and the reducing agent can be one or more of citric acid, sodium borohydride, oxalic acid, and tannic acid;

[0016] Step 2, adding organosilane and silicate clay into a solvent for reaction to obtain organosilane-modified silicate clay;

[0017] Wherein: the solvent can be a solution of water and ethanol mixed in any proportion;

[0018] Step 3: mixing the metal nanoparticle solution coated with the platinum-based nanozyme with the organosilane-modified silicate clay solution to obtain the silicate clay-loaded platinum nanozyme.

[0019] In one embodiment of the present invention, the organosilane is 3-aminopropyltriethoxysilane, the silicate clay is attapulgite, and the metal nanoparticles are gold nanoparticles. In step 3, the mass ratio of the metal nanoparticles coated with the platinum-based nanozyme to the organosilane-modified silicate clay is 1:2.

[0020] The use of the above-mentioned silicate clay-loaded platinum nanozyme in the preparation of drugs for preventing and / or treating digestive tract diseases.

[0021] Furthermore, the digestive tract disease is esophagitis, gastritis, gastric ulcer, colitis, acute diarrhea, and chronic diarrhea.

[0022] The experimental study of the present invention found (see the example section for specific experimental steps and data) that the drug delivery system has a good effect on reducing the ROS level of colon epithelial cells in mice modeled with colorectal inflammation. Among them, the gold platinum nanozyme loaded on attapulgite has a better therapeutic effect than the gold platinum nanozyme loaded on montmorillonite. The gold platinum nanozyme loaded on attapulgite reduces the ROS level of colon epithelial cells to a level similar to that of the blank control group, showing excellent ROS scavenging ability. In addition, DAI data and colorectal length also show the therapeutic effect of the drug delivery system for colorectal inflammation.

[0023] The present invention has a good therapeutic effect on inflammatory diseases in the digestive system. The silicate clay is modified with organosilane to enhance the enrichment capacity of the silicate clay for platinum-based nanozymes. After oral administration, the silicate clay can adhere to the inflammatory site, continuously exert the excellent ROS scavenging ability of the platinum-based nanozymes, alleviate tissue damage caused by excessive ROS, and accelerate tissue repair and inflammation relief.

[0024] The present invention uses silicate clay to load platinum-based nanozymes, thereby enhancing the enrichment and accumulation of platinum-based nanozymes in the site of digestive tract inflammation after oral administration, and achieves the treatment, relief or prevention effect of digestive tract inflammatory diseases through the continuous scavenging effect of platinum-based nanozymes on ROS. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Comparison of the electric potentials of montmorillonite and attapulgite before and after loading with different organosilanes.

[0026] Figure 2 Comparison of the loading capacity of montmorillonite and attapulgite for gold-platinum nanozymes before and after modification.

[0027] Figure 3 These are the SEM results of gold-platinum nanozymes loaded on montmorillonite and gold-platinum nanozymes loaded on attapulgite.

[0028] Figure 4 These are the elemental mapping results of gold-platinum nanozymes loaded on montmorillonite and gold-platinum nanozymes loaded on attapulgite.

[0029] Figure 5 These are the catalase activity results of gold-platinum nanozymes before and after loading with montmorillonite / attapulgite.

[0030] Figure 6 DAI data of gold-platinum nanozyme before and after loading with montmorillonite / attapulgite.

[0031] Figure 7 Images of the colorectum before and after loading of gold-platinum nanozymes with montmorillonite / attapulgite.

[0032] Figure 8 The length of the colorectum before and after the gold-platinum nanozyme was loaded with montmorillonite / attapulgite.

[0033] Fig. 9 The flow cytometry results of ROS in epithelial cells before and after the gold-platinum nanozyme was loaded with montmorillonite / attapulgite.

[0034] Fig.10 The ROS levels of epithelial cells before and after the gold-platinum nanozymes were loaded with montmorillonite / attapulgite. DETAILED DESCRIPTION

[0035] The preferred embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that the following examples are provided only for the purpose of illustration and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.

[0036] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0037] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0038] Example 1

[0039] Preparation of platinum nanozymes coated with gold nanoparticles supported on silicate minerals

[0040] Step 1, add 4 mg of chloroauric acid trihydrate and 100 μL of 25 g / L sodium citrate solution to 40 mL of ultrapure water and stir for 10 minutes (the molar ratio of chloroauric acid trihydrate to sodium citrate is 1:1), then slowly add 600 μL of 1.2 g / L sodium borohydride solution (the molar ratio of chloroauric acid trihydrate to sodium borohydride is 1:1.8) dropwise while stirring, add 4 mg of chloroplatinic acid hexahydrate after stirring for 20 minutes, and slowly add 600 μL of 1.2 g / L sodium borohydride solution (the molar ratio of chloroplatinic acid hexahydrate to sodium borohydride is 1:2.4) dropwise while stirring, and react on ice for 20 minutes to obtain platinum nanozyme coated with gold nanoparticles, namely gold platinum nanozyme (AuPt).

[0041] Step 2, add 10g of 3-aminopropyltriethoxysilane to 1000mL of water / ethanol mixed solution (volume ratio 1:3) and keep the temperature at 80°C. Add 10g of montmorillonite (MMT) or attapulgite (PAL), react at 80°C for 6h, and centrifuge to discard the supernatant. Resuspend the precipitate with 1000mL of water / ethanol mixed solution (volume ratio 1:3), centrifuge to discard the supernatant, repeat 6 times, and obtain 3-aminopropyltriethoxysilane-modified montmorillonite (APTES-MMT) or 3-aminopropyltriethoxysilane-modified attapulgite (APTES-PAL).

[0042] Step 3, incubate 0.2 g / L gold nanoparticle-coated platinum nanozyme solution with equal volumes of 0.4 g / L 3-aminopropyltriethoxysilane-modified montmorillonite / 3-aminopropyltriethoxysilane-modified attapulgite with stirring for 30 min, centrifuge and discard the supernatant, resuspend the precipitate with ultrapure water, centrifuge and discard the supernatant, repeat 3 times to obtain montmorillonite-loaded gold-platinum nanozyme (AuPt@MMT) or attapulgite-loaded gold-platinum nanozyme (AuPt@PAL).

[0043] Test Example 1

[0044] Verification of different organosilane modification on montmorillonite / attapulgite

[0045] Step 1, add 10g of vinyl trimethoxysilane to 1000mL of water / ethanol mixed solution (volume ratio 1:3) and keep the temperature at 80°C. Add 10g of montmorillonite (MMT) or attapulgite (PAL), react at 80°C for 6h, and centrifuge to discard the supernatant. Resuspend the precipitate with 1000mL of water / ethanol mixed solution (volume ratio 1:3), centrifuge to discard the supernatant, repeat 6 times to obtain vinyl trimethoxysilane-modified montmorillonite (VTMS-MMT) or vinyl trimethoxysilane-modified attapulgite (VTMS-PAL).

[0046] Step 2, take 10 mg of MMT, PAL, APTES-MMT, APTES-PAL, VTMS-MMT and VTMS-PAL respectively, add 1 mL of deionized water to dilute, transfer to the sample cell (DTS1070), and use Malvern particle size analyzer to detect the sample potential.

[0047] like Figure 1 As shown, the potentials of APTES-MMT, APTES-PAL, VTMS-MMT and VTMS-PAL were all increased compared with MMT and PAL, indicating that 3-aminopropyltriethoxysilane and vinyltrimethoxysilane were successfully loaded on the surfaces of the two silicates.

[0048] Test Example 2

[0049] Comparison of the ability of montmorillonite / attapulgite to load gold-platinum nanozymes before and after modification with 3-aminopropyltriethoxysilane

[0050] The concentration of 0.5 mg / mL gold platinum nanozyme solution was diluted in half in 6 gradients, the absorbance at a wavelength of 372 nm was detected, and a concentration-absorbance standard curve was drawn. 1 mg of montmorillonite or attapulgite before and after modification with 3-aminopropyltriethoxysilane was added to 10 mL of 0.5 mg / mL gold platinum nanozyme solution, and incubated at 37 ° C for 2 h. The supernatant of the solution was centrifuged and the gold platinum nanozyme loading capacity of montmorillonite or attapulgite before and after modification with 3-aminopropyltriethoxysilane was calculated by comparing the change in the absorbance of the solution before and after incubation. The experimental data were processed with graphpad software.

[0051] like Figure 2 As shown, 3-aminopropyltriethoxysilane modification can significantly increase the loading capacity of montmorillonite and attapulgite for gold-platinum nanozymes.

[0052] Test Example 3

[0053] Scanning electron microscopy characterization of montmorillonite-nanozyme / attapulgite-nanozyme

[0054] 10 μL of AuPt@MMT / AuPt@PAL was dropped onto tin foil and placed in a fume hood to dry. The tin foil containing the sample was cut into small squares and pasted onto the conductive tape adhered to the sample holder. The sample powder that was not firmly adhered to the tin foil was blown away with a spray gun. The samples were imaged under a scanning electron microscope and the surface elements were scanned using an X-ray energy dispersive spectrometer (EDS).

[0055] like Figure 3 As shown, the attachment of gold-platinum nanozymes on the montmorillonite / attapulgite surface can be observed.

[0056] like Figure 4 As shown, the surface gold and platinum elements are attached to the surface of montmorillonite / attapulgite in a uniform state, indicating that the gold-platinum nanozyme can be loaded on the surface of montmorillonite / attapulgite in a stable state.

[0057] Test Example 4

[0058] Determination of catalase activity of nanozymes and montmorillonite-nanozymes / attapulgite-nanozymes

[0059] Catalase activity was detected using a catalase (CAT) activity detection kit (ammonium molybdate method), purchased from Beijing Solebow Technology Co., Ltd. The specific experimental steps were carried out according to the steps described in the kit instructions. The experimental data were processed using graphpad software.

[0060] like Figure 5As shown in the figure, AuPt nanozymes have peroxidase activity and can convert hydrogen peroxide into water and oxygen. The catalase activity of AuPt@MMT and AuPt@PAL also decreased compared with AuPt. Among them, the CAT activity of AuPt@MMT and AuPt@PAL decreased from 139.77U / mg of AuPt to 89.63U / mg and 109.40U / mg, respectively.

[0061] Test Example 5

[0062] Effect on the Disease Activity Index (DAI) score of mice

[0063] The experimental animals were C57 mice, female, 6 weeks old, weighing 18-20 g. The laboratory room temperature was 23-25°C, the relative humidity was 40%-60%, ventilation was provided by a ventilator, the natural light source was 12 h / day, and the mice were kept in cages, with 5 mice in each cage, and the cages were cleaned every three days.

[0064] The drinking water of the experimental group was replaced with 3% dextran sulfate sodium solution (DSS), produced by Yisheng Biotechnology (Shanghai) Co., Ltd., batch number 60316ES76. From the third day on, the drug-treated group was orally administered once every other day, for a total of 4 times. The dosages were: AuPt 15 mg / kg, AuPt@MMT 45 mg / kg, AuPt@PAL 45 mg / kg, and the administration volume was 0.1 mL / mouse.

[0065] The blank control group was given an equal volume of normal saline. The positive drug control group was given mesalazine (manufactured by Sigma-Aldrich (Shanghai) Trading Co., Ltd.), with an oral administration dose of 50 mg / kg for mice and a dosing volume of 0.1 mL / mouse.

[0066] The DAI data of mice were recorded from the fourth day onwards. The specific scoring method is shown in the table below.

[0067]

[0068] The experimental data were processed using GraphPad software.

[0069] like Figure 6 As shown, the DAI data showed that the AuPt@PAL group had the best therapeutic effect, and the relief of enteritis in mice was significantly better than that in the positive drug group; while the AuPt@MMT group and AuPt group also had similar therapeutic effects to the positive drug group.

[0070] Test Example 6

[0071] Effects on colorectal length in mice

[0072] The experimental animals were C57 mice, female, 6 weeks old, weighing 18-20 g. The laboratory room temperature was 23-25°C, the relative humidity was 40%-60%, ventilation was provided by a ventilator, the natural light source was 12 h / day, and the mice were kept in cages, with 5 mice in each cage, and the cages were cleaned every three days.

[0073] The drinking water of the experimental group was replaced with 3% dextran sulfate sodium solution (DSS), produced by Yisheng Biotechnology (Shanghai) Co., Ltd., batch number 60316ES76. From the third day on, the drug-treated group was orally administered once every other day, for a total of 4 times. The dosages were: AuPt 15 mg / kg, AuPt@MMT 45 mg / kg, AuPt@PAL 45 mg / kg, and the administration volume was 0.1 mL / mouse.

[0074] The blank control group (PBS group) was given an equal volume of PBS. The positive drug control group was mesalazine (manufactured by Sigma-Aldrich (Shanghai) Trading Co., Ltd.), with an oral administration dose of 50 mg / kg for mice and a dosing volume of 0.1 mL / mouse.

[0075] The mice were killed and dissected on the 11th day. The complete colorectum was dissected out from the anus of the mice, and the length of the colorectum was measured. The data of this experiment were processed using GraphPad software.

[0076] like Figure 7 and Figure 8 As shown, the AuPt@PAL group had the best therapeutic effect, and the relief of enteritis in mice was significantly better than that in the positive drug group; while the AuPt@MMT group and AuPt group also had similar therapeutic effects to the positive drug group.

[0077] Test Example 7

[0078] Effects on ROS levels in mouse intestinal epithelial cells

[0079] The experimental animals were C57 mice, female, 6 weeks old, weighing 18-20 g. The laboratory room temperature was 23-25°C, the relative humidity was 40%-60%, ventilation was provided by a ventilator, the natural light source was 12 h / day, and the mice were kept in cages, with 5 mice in each cage, and the cages were cleaned every three days.

[0080] The drinking water of the experimental group was replaced with 3% sodium dextran sulfate solution, produced by Yisheng Biotechnology (Shanghai) Co., Ltd., batch number 60316ES76. From the third day on, the drug-treated group was orally administered once every other day, for a total of 4 times. The dosages were: AuPt 15mg / kg, AuPt@MMT 45mg / kg, AuPt@PAL 45mg / kg, and the administration volume was 0.1mL / mouse.

[0081] The blank control group (PBS group) was given an equal volume of PBS. The positive drug control group was mesalazine (manufactured by Sigma-Aldrich (Shanghai) Trading Co., Ltd.), the oral administration dose for mice was 50 mg / kg, and the administration volume was 0.1 mL / mouse.

[0082] On the 11th day, the mice were killed and dissected. The complete colorectum was dissected from the mouse anus. 1 cm of the colon was cut longitudinally, cut into square segments, added to 1640 culture medium containing 1 mM dithiothreitol and oscillated at 37°C for 20 minutes. After vortexing for 30 seconds, filter with a 200-mesh nylon filter and wash twice with PBS. A blank group without fluorescent probe labeling was set up in the control group. Each group was incubated in 1640 culture medium containing 10 μM DCFH-DA probe at 37°C in the dark for 20 minutes and washed twice with PBS. The fluorescence intensity of the FITC channel was detected by flow cytometry.

[0083] The experimental data were processed using FlowJo 10.0 and GraphPad software.

[0084] like Fig. 9 , Fig.10 As shown, the ROS level of colon epithelial cells in the AuPt@PAL group mice was reduced to a level similar to that of the blank control group, demonstrating the excellent ROS scavenging ability of AuPt@PAL.

Claims

1. A platinum nanozyme supported by silicate clay, characterized in that: It includes a silicate carrier and a platinum nanozyme, wherein the platinum nanozyme is loaded on the silicate carrier; The silicate carrier is organosilane-modified silicate clay; The platinum nanozyme is a metal nanoparticle coated with a platinum-based nanozyme.

2. The silicate clay-supported platinum nanozyme according to claim 1, characterized in that: The organosilane is selected from one or more of 3-aminopropyltriethoxysilane, N-(β-aminoethyl)-γ-aminopropyltrimethoxysilane, 3-aminopropyltrimethoxysilane, γ-diethylenetriaminepropylmethyldimethoxysilane, γ-aminopropyltriethoxysilane, N-(β-aminoethyl)-γ-aminopropyltrimethoxysilane, γ-aminopropyltriethoxysilane, N-(β-aminoethyl-γ-aminopropyl)methyldimethoxysilane, and γ-aminopropylmethyldiethoxysilane.

3. The silicate clay-supported platinum nanozyme according to claim 2, characterized in that: The silicate clay is selected from one or more of montmorillonite, attapulgite, diatomite, fluorite, diatomite, kaolin, illite, chlorite, sepiolite, zeolite and talc.

4. The silicate clay-supported platinum nanozyme according to claim 1, characterized in that: The metal nanoparticles are selected from one or more of gold nanoparticles, silver nanoparticles, chromium nanoparticles, copper nanoparticles, and lead nanoparticles.

5. Use of the silicate clay-loaded platinum nanozyme according to claim 1 in the preparation of drugs for preventing and / or treating digestive tract diseases.

6. The use according to claim 1, characterized in that: The digestive tract diseases are esophagitis, gastritis, gastric ulcer, colitis, acute diarrhea, and chronic diarrhea.